Eliasson, Björn
Lyngfelt, Lovisa
Strömblad, Sven-Olof
Franzén, Stefan
Eeg-Olofsson, Katarina
Funding for this research was provided by:
Swedish Association of Local Authorities and Regions
The Swedish state under the agreement between the Swedish government and the county councils
sanofi
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
University of Gothenburg
Article History
Received: 2 July 2022
Accepted: 20 October 2022
First Online: 26 October 2022
Competing interests
: BE reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Mundipharma, RLS Global and Sanofi, all outside the submitted work. LL declares no conflict of interest relevant to this article. S-OS is employed by Sanofi. However, the views expressed in this study are his own and not those of Sanofi.SF is employed by AstraZeneca. However, the views expressed in this study are his own and not those of AstraZeneca. KEO has received personal lecture fees from Sanofi, Eli Lilly, Novo Nordisk and Abbott, all outside the submitted work.